Atrial Fibrillation in Active Cancer Patients

Summary

Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.

Conditions

• Cancer
• Drug Toxicity
• Atrial Fibrillation
• Cardiovascular Complication

Interventions

OTHER

occurence of atrial fibrillation

all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).

Sponsors & Collaborators

• University Hospital, Marseille, France

  collaborator UNKNOWN

• Hospices Civils de Lyon, France

  collaborator UNKNOWN

• Centre Francois Baclesse, Caen, France

  collaborator UNKNOWN

• University Hospital of Saint-Etienne, France

  collaborator UNKNOWN

• Hôpital Lariboisière Fernand Widal, Paris, France

  collaborator UNKNOWN

• Institut de Cancérologie de l'Ouest Nantes, France

  collaborator UNKNOWN

• Fundacion Cardio Onco, Santiago, Chile

  collaborator UNKNOWN

• Hunter New England Area Health Service, University of Newcastle, Australia

  collaborator UNKNOWN

• University Hospital, Rouen

  collaborator OTHER

• University Hospital, Caen

  lead OTHER

Principal Investigators

• Joachim Alexandre, MD, PhD · Caen Normandy University Hospital, France

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-09-01

Primary Completion

2025-09-01

Completion

2026-01-01

Countries

• France

Study Locations